Journal of Bone and Mineral Metabolism最新文献_第6页

Bone development by Hedgehog and Wnt signaling, Runx2, and Sp7. 通过刺猬和 Wnt 信号、Runx2 和 Sp7 实现骨骼发育。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2024-10-01 DOI: 10.1007/s00774-024-01551-1

Toshihisa Komori

{"title":"Bone development by Hedgehog and Wnt signaling, Runx2, and Sp7.","authors":"Toshihisa Komori","doi":"10.1007/s00774-024-01551-1","DOIUrl":"10.1007/s00774-024-01551-1","url":null,"abstract":"Hedgehog and canonical Wnt signaling pathways and the transcription factors Runx2 and Sp7 are essential for osteoblast differentiation. Ihh is necessary for the commitment of perichondrial mesenchymal cells to Runx2+ osteoprogenitors and for the formation of the bone collar and primary spongiosa. Runx2 is needed for osteoblast differentiation during both endochondral and intramembranous ossification. It regulates the commitment of mesenchymal cells to osteoblast-lineage cells and their proliferation by inducing the expression of Hedgehog, Fgf, Wnt, Pthlh signaling pathway genes, and Dlx5. The Runx2-induced expression of Fgfr2 and Fgfr3 is important for the proliferation of osteoblast-lineage cells. Runx2 induces Sp7 expression and Runx2+ osteoprogenitors become Runx2+Sp7+ preosteoblasts. Runx2, Sp7, and canonical Wnt signaling induce the differentiation of preosteoblasts into osteoblasts. Canonical Wnt signaling, but not Sp7, enhances the proliferation of osteoblast-lineage cells. In mature osteoblasts, Runx2 plays an important role in the expression of major bone matrix protein genes, including Col1a1, Col1a2, Spp1, Ibsp, and Bglap/Bglap2. The canonical Wnt signaling pathway is also crucial for bone formation by mature osteoblasts. Sp7 is needed for osteocytes to acquire a sufficient number of processes and a reduction in these processes results in osteocyte apoptosis and cortical porosity.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"33-38"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histological assessments for anabolic effects in teriparatide/abaloparatide administered rodent models. 特立帕肽/阿巴帕肽给药啮齿动物模型合成代谢作用的组织学评估。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI: 10.1007/s00774-024-01562-y

Tomoka Hasegawa, Tomomaya Yamamoto, Mai Haraguchi-Kitakamae, Hiromi Hongo, Yan Shi, Jiaxin Cui, Xuanyu Liu, Qi Yao, Miki Abe, Haruhi Maruoka, Ayako Yokoyama, Tamaki Sekiguchi, Akito Makino, Norio Amizuka

{"title":"Histological assessments for anabolic effects in teriparatide/abaloparatide administered rodent models.","authors":"Tomoka Hasegawa, Tomomaya Yamamoto, Mai Haraguchi-Kitakamae, Hiromi Hongo, Yan Shi, Jiaxin Cui, Xuanyu Liu, Qi Yao, Miki Abe, Haruhi Maruoka, Ayako Yokoyama, Tamaki Sekiguchi, Akito Makino, Norio Amizuka","doi":"10.1007/s00774-024-01562-y","DOIUrl":"10.1007/s00774-024-01562-y","url":null,"abstract":"Parathyroid hormone (PTH) is thought to induce remodeling-based bone formation by promoting osteoclastic activity, a process known as cellular coupling. Our research has shown that the frequency of PTH administration affects trabecular number and thickness. High-frequency PTH administration induced remodeling-based bone formation, while less frequent administration induced both remodeling-based and modeling-based bone formation. Additionally, we found that specific bone sites influence whether remodeling-based or modeling-based bone formation is more likely to occur. Additionally, while PTH significantly increases trabecular bone, it also causes cortical porosis. Our research on the femoral diaphysis showed that PTH administration resulted in the invasion of blood vessels and osteoclasts into the cortical bone. Abaloparatide acts similarly to teriparatide through the parathyroid hormone receptor type 1 (PTH1R) but may have a wider anabolic window due to its lesser impact on bone resorption. Our mouse studies with abaloparatide showed similar results to those seen in human patients, with increased preosteoblastic cell populations and wider anabolic windows when compared with teriparatide. Abaloparatide-induced bone formation cannot be explained solely by remodeling-based bone formation, indicating the need for further research into modeling-based bone formation.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"46-56"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Responders and non-responders to romosozumab treatment. 对罗莫索单抗治疗有反应和无反应。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2024-12-07 DOI: 10.1007/s00774-024-01570-y

Ayako Tominaga, Keiji Wada, Yoshiharu Kato, Ken Okazaki

{"title":"Responders and non-responders to romosozumab treatment.","authors":"Ayako Tominaga, Keiji Wada, Yoshiharu Kato, Ken Okazaki","doi":"10.1007/s00774-024-01570-y","DOIUrl":"10.1007/s00774-024-01570-y","url":null,"abstract":"Introduction: Romosozumab is an anti-sclerostin antibody drug with potent bone formation-promoting and bone resorption-inhibiting properties. It enhances bone mineral density and has a novel effect in preventing fractures. However, there have been reports of non-responders to romosozumab.Findings: If the least significant change is defined as 3%, only 2-12% of patients with spine osteoporosis are non-responders, and romosozumab is highly effective in this population. Low-type 1 amino-terminal propeptide (P1NP) levels during the early treatment phase are associated with non-responders early in treatment. The researchers found a cutoff value of 50.3 μg/L of P1NP in the first month of treatment. In contrast, hip osteoporosis does not respond (54-57% of the time). Low P1NP levels at the start of treatment increase the risk of non-responders. The cutoff value for P1NP was reported as 53.7 μg/L at the beginning of treatment. However, failure to meet these cutoff values does not necessarily indicate that the patient is a non-responder and does not justify a change in drug administration.Conclusions: In spine osteoporosis, romosozumab demonstrates high effectiveness, with approximately 2-12% of patients showing no response. However, in hip osteoporosis, approximately 54-57% do not respond to the treatment with romosozumab.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"18-21"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sequential and combination therapy with romosozumab. romosozumab序贯和联合治疗。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2025-03-01 DOI: 10.1007/s00774-025-01590-2

Tomonori Kobayakawa

{"title":"Sequential and combination therapy with romosozumab.","authors":"Tomonori Kobayakawa","doi":"10.1007/s00774-025-01590-2","DOIUrl":"10.1007/s00774-025-01590-2","url":null,"abstract":"The introduction of the bone-forming agent romosozumab has led to a dramatic improvement in osteoporosis treatment. While bisphosphonates remain the most commonly used drugs for the treatment of osteoporosis, it is recommended that patients at high risk of fractures initially receive bone-forming agents, followed by sequential treatment with bone resorption inhibitors. Romosozumab, an anti-sclerostin antibody, is an osteoporosis medication with both bone formation-stimulating and bone resorption-inhibiting properties, demonstrating significant efficacy in increasing bone mineral density and reducing fracture risk. However, due to the limited 12-month initial treatment period, sequential therapy with other osteoporosis medications is necessary following the completion of romosozumab administration. Due to the current lack of sufficient evidence regarding the use of romosozumab in sequential and combination therapies, this review aims to evaluate the efficacy of romosozumab as a sequential treatment, its effectiveness in combination with other agents, and its role in reducing new fragility fractures and increasing bone mineral density following sequential therapy after romosozumab. This review will summarize clinical trials and real-world data, providing valuable information to guide treatment decisions.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"10-17"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular safety of osteoanabolic agents. 骨合成代谢药物的心血管安全性。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2025-01-17 DOI: 10.1007/s00774-025-01580-4

Yasuhiro Takeuchi

{"title":"Cardiovascular safety of osteoanabolic agents.","authors":"Yasuhiro Takeuchi","doi":"10.1007/s00774-025-01580-4","DOIUrl":"10.1007/s00774-025-01580-4","url":null,"abstract":"Purpose: Several osteoanabolic agents have been developed to build new bone more efficiently than anti-resorptive drugs. Among them, romosozumab, an anti-sclerostin antibody, is a potent pharmacological tool to prevent fractures in osteoporosis patients. The efficacy of romosozumab in preventing osteoporotic fractures is robust. However, there remains a concern about increased cardiovascular (CV) adverse events related to romosozumab. Available data have been reviewed to address this concern.Methods: Published articles on romosozumab of which pivotal randomized controlled trials (RCTs), meta-analyses of RCTs, pharmacovigilance investigations, and retrospective observational clinical studies using real-world data were collected through PubMed and other available tools.Results: Meta-analyses of RCTs of romosozumab compared to placebo and other anti-osteoporosis drugs have left room for controversy in the CV safety of romosozumab. Investigations of the real-world data also provide no conclusive evidence in this issue.Conclusion: We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"26-32"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osteoanabolic agents for fracture prevention: bone building beyond bone protection. 预防骨折的骨合成代谢剂：超越骨保护的骨建设。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 DOI: 10.1007/s00774-025-01591-1

Yasuhiro Takeuchi, Hiroshi Hagino

引用次数: 0

Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. 特立帕肽、阿帕帕肽和罗莫索单抗对绝经后骨质疏松症的临床效果。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2025-01-01 Epub Date: 2024-07-15 DOI: 10.1007/s00774-024-01536-0

Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Ken Nakata, Seiji Okada

{"title":"Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.","authors":"Kosuke Ebina, Yuki Etani, Takaaki Noguchi, Ken Nakata, Seiji Okada","doi":"10.1007/s00774-024-01536-0","DOIUrl":"10.1007/s00774-024-01536-0","url":null,"abstract":"In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of vertebral or hip fractures that markedly diminish life expectancy, the immediate reduction of fracture risk through the administration of osteoanabolic agents could be beneficial. Teriparatide, available in daily, once-weekly, or twice-weekly dosages, along with abaloparatide and romosozumab, constitutes a trio of such agents. Each of these medications is defined by unique characteristics, distinct efficacy profiles, and specific adverse effects. There is growing evidence to suggest that these agents have a superior effect on enhancing bone mineral density and reducing fracture incidence when compared to traditional bisphosphonate therapies. Nonetheless, their employment demands thorough consideration of clinical indications, which includes evaluating economic factors, the frequency of injections required, and the potential for adverse effects. The objective of this review is to consolidate the current evidence focusing primarily on the efficacy of these agents, with the goal of enhancing understanding and aiding in making more informed treatment decisions, particularly for those individuals who are at an elevated risk of fractures.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"3-9"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

List of reviewers 2024. 审稿人名单2024。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-12-04 DOI: 10.1007/s00774-024-01565-9

引用次数: 0

Journal of Bone and Mineral Metabolism Best Paper Award 2024. 骨与矿物质代谢杂志2024年最佳论文奖。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-30 DOI: 10.1007/s00774-024-01566-8

引用次数: 0

Incidence of four major osteoporotic fragility fractures among older individuals in Sado, Japan, in 2020. 2020 年日本佐渡地区老年人四种主要骨质疏松性脆性骨折的发病率。

IF 2.4 3区医学

Journal of Bone and Mineral Metabolism Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI: 10.1007/s00774-024-01529-z

Norio Imai, Asami Nozaki, Yugo Shobugawa, Kentaro Higuchi, Yoshihiro Suda, Takeo Oinuma, Hayato Suzuki, Yoji Horigome, Hiroyuki Kawashima

{"title":"Incidence of four major osteoporotic fragility fractures among older individuals in Sado, Japan, in 2020.","authors":"Norio Imai, Asami Nozaki, Yugo Shobugawa, Kentaro Higuchi, Yoshihiro Suda, Takeo Oinuma, Hayato Suzuki, Yoji Horigome, Hiroyuki Kawashima","doi":"10.1007/s00774-024-01529-z","DOIUrl":"10.1007/s00774-024-01529-z","url":null,"abstract":"Introduction: This study compared the 2020 incidence of fragility fractures in Sado City with those from 2004 to 2015.Materials and methods: Data from patients aged ≥ 60 years living in Sado City with fragility fractures in the hip, vertebral, distal radius, and proximal humerus between January 1 and December 31, 2020, were collected. We examined the number and incidence of four types of osteoporotic fractures in the older population aged ≥ 60 years living in Sado City in 2020. We compared the results with those of the 2004, 2010, and 2015 surveys, examining the temporal change and trend in the incidence of the four fracture types in this population. We investigated the use rate of anti-osteoporotic medications and the relationship between their administration and the occurrence of fragility fractures.Results: The age-specific incidence of hip fractures slightly decreased from 2015. However, the incidence of the other three fractures slightly increased, although the difference was not statistically significant. The incidence of hip fractures markedly increased in the 80 s. In 2020, the percentage of patients taking anti-osteoporotic agents before the occurrence of fractures decreased to 12.4% from 14.5% in 2015; it increased from 4% in 2004 to 7.6% in 2010.Conclusion: The 2020 incidence of the four fractures did not decrease, and the percentage of patients receiving anti-osteoporotic agents did not increase. A higher frequency of osteoporosis treatment is necessary to reduce the incidence of fragility fractures. We recommend using anti-osteoporotic agents to prevent hip fractures among individuals in their mid-70 s and above.","PeriodicalId":15116,"journal":{"name":"Journal of Bone and Mineral Metabolism","volume":" ","pages":"647-652"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0